A Phase I, multi-center, open-label, dose escalation study of LXS196, an oral protein kinase C inhibitor, in patients with metastatic uveal melanoma
Study of LXS196 in Patients with Uveal Melanoma
Sponsor: Novartis
Enrolling: Male and Female Patients
IRB Number: AAAR6254
U.S. Govt. ID: NCT02601378
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: You are invited to join voluntarily in a clinical research study to find out if the drug LXS196 alone or in combination with HDM201 is safe and has beneficial effects in people who have metastatic uveal melanoma. The purpose of this study is to determine the highest dose of LXS196 that can be given safely without unacceptable side effects as a single drug or in combination with HDM201. The study will also examine how much and for how long LXS196 as a single drug or in combination with HDM201 stays in your blood, and if LXS196 has an effect on the tumor growth both as a single drug and in combination with HDM201. You will receive LXS196 or LSX196 in combination with HDM201 for approximately 9 months. After you finish, your study doctor will continue to watch you for side effects and follow your condition for 30 days after the last dose of study treatment.
This study is closed
Richard Carvajal, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with uveal melanoma with confirmed metastatic disease? Yes No
Have you received treatment before or did your previous treatment cause disease progression? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator